Menu
Search
|

Menu

Close
X

Vermillion Inc VRML.OQ (NASDAQ Stock Exchange Capital Market)

0.62 USD
-0.06 (-8.16%)
As of Jul 13
chart
Previous Close 0.68
Open 0.67
Volume 67,334
3m Avg Volume 23,331
Today’s High 0.67
Today’s Low 0.61
52 Week High 2.09
52 Week Low 0.61
Shares Outstanding (mil) 70.04
Market Capitalization (mil) 43.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
3
FY16
3
FY15
2
EPS (USD)
FY18
-0.047
FY17
-0.201
FY16
-0.287
FY15
-0.407
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
14.27
8.07
Price to Book (MRQ)
vs sector
30.04
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
130.75
17.39
LT Debt to Equity (MRQ)
vs sector
115.74
13.21
Return on Investment (TTM)
vs sector
-196.72
13.23
Return on Equity (TTM)
vs sector
-298.69
15.28

EXECUTIVE LEADERSHIP

James LaFrance
Chairman of the Board, Since 2015
Salary: $258,601.00
Bonus: $129,375.00
Valerie Palmieri
President, Chief Executive Officer, Since 2015
Salary: $57,292.00
Bonus: $22,800.00
Robert Beechey
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Donald Munroe
Senior Vice President - Business Development, Chief Scientific Officer, Since 2013
Salary: $269,039.00
Bonus: $66,000.00
Chris Goulart
Senior Vice President - Commercial Operations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Suite 100
12117 Bee Caves Road Building Th
AUSTIN   TX   78738

Phone: +1512.5190400

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

SPONSORED STORIES